Astrazeneca

In: Business and Management

Submitted By rogersmd1974
Words 1230
Pages 5
Research Paper

AstraZeneca Pharmaceuticals, (AZN) is one of the world's leading pharmaceutical companies with 57,000 employees worldwide in over 100 countries. Its corporate headquarters are in London, research and development headquarters are in Södertälje, Sweden, and its manufacturing facilities employ 9,600 people in 16 different countries. The company operates fourteen research and development sites in eight countries and has sales in over 100 countries around the world. AstraZeneca focuses its pharmaceutical business on seven key therapeutic areas: anesthesia and pain control, cardiovascular, central nervous system, gastrointestinal (it is a world leader in this therapeutic area), infection, oncology, and respiratory. Its product range includes such blockbusters as Nexium, Crestor, Seroquel, and Symbicort.
AstraZeneca was formed as the result of the 1999 merger of two European pharmaceuticals companies: Astra AB of Sweden, a maker of pharmaceutical products and medical devices, and Zeneca PLC of the United Kingdom, a bioscience company focusing on pharmaceuticals, agricultural and specialty chemicals, and disease-specific healthcare services. One year after its merger, the company achieved sales of US$15.8 billion, with an operating profit of US$4 billion. In 2011, company sales and operating profit were $33.6 billion and $13.2 billion respectively.
AstraZeneca is one of the world's largest pharmaceutical companies, with FY2011 sales of $33.27 billion and $10.98 billion in profits before taxes. AstraZeneca's wide-ranging portfolio of products includes some of the world's most successful drugs. Analysts credit AstraZeneca with having one of the most diversified drug portfolios in the pharmaceutical industry. In all, AstraZeneca has 9 blockbuster drugs (with $1 billion or more in annual sales) in five different therapeutic categories. All in all…...

Similar Documents

An Overview of the Uk Pharmaceutical Industry

...An Overview of the UK Pharmaceutical Industry The Pharmaceutical Industry in the UK is the second largest contributor to Gross Domestic Product behind Financial Services. There are several very big players in the UK with GlaxoWelcome & SmithKline Beecham who merged in January 2000 to become Glaxo SmithKline and AstraZeneca being the two largest UK based companies. Almost all the other major pharmaceutical companies operating in the UK have undergone or are in the process of undergoing mergers and acquisitions, including AstraZeneca, Pfizer and Warner Lambert, Shire and Roberts, and Celltech with Chiroscience and Medeva. The UK pharmaceutical market is a successful, research-driven, high-technology industry. The UK market is dynamic and increasingly competitive and, it ranks third after Germany and Switzerland in the global pharmaceutical industry rankings in terms of trade balance. According to the Association of the British Pharmaceutical Industry (Abpi), the industry employs around 75,000 people, of whom over 25% are graduates. Introduction to AstraZeneca AstraZeneca is one of the world’s leading pharmaceutical companies, with a major presence in the UK. Their business is focused on providing innovative, effective medicines that make a real difference in important areas of healthcare. Other facilities in the UK include research and development, sales and marketing and manufacturing. In 2008 AstraZeneca’s total contribution to wealth creation was £4.1...

Words: 1059 - Pages: 5

Pfizer and the Challenges of the Global Pharmaceutical Industry

... important to know- what percentages of revenue do pharmaceutical companies get for each product segment. Table 1.1 contains information about these major pharmaceutical companies that are sorted in the order of their 2007 revenues from the sales of pharmaceutical products. Table 1.1. Major pharmaceutical companies Analysis. Company | Location | Total Revenue | Product | Product Profit in Million, USD | Revenue % | Johnson & Johnson | U.S. | 53,324 | Risperdal | 11,053 | 20.7% | Pfizer | U.S. | 52,415 | Lipitor | 19,337 | 36.9% | GlaxoSmithKline | UK | 42,731 | Seretide/Advair | 9,915 | 23.2% | Novartis | Switzerland | 37,020 | Sandoz | 7,175 | 19.4% | Sanofi-Aventis | France | 36,998 | Plavix | 5,026 | 13.6% | AstraZeneca | UK | 26,475 | Nexium | 6,043 | 22.8% | Merck & Co. | U.S. | 22,636 | Zocor | 4,434 | 19.6% | Abbott | U.S. | 22,476 | Ogastro/Prevacid | 1,717 | 7.6% | Wyeth | U.S. | 20,351 | Effexor | 4,197 | 20.6% | Eli Lilly | U.S. | 15,691 | Zyprexa | 2,663 | 17.0% | Source: Case written by Nell, Phillip and CNN Fortune & Money As Table 1.1 shows, the majority of the largest pharmaceutical companies are not diversified. The top companies are Pfizer, GSK and AstraZeneca. It is clear Pfizer has the highest percent of their revenues coming from sales of pharmaceutical products like Lipitor. Although they develop and manufacture other health care products, Pfizer still have pharmaceutical divisions as the core of their business that......

Words: 582 - Pages: 3

Astrazeneca

...Research Paper AstraZeneca Pharmaceuticals, (AZN) is one of the world's leading pharmaceutical companies with 57,000 employees worldwide in over 100 countries. Its corporate headquarters are in London, research and development headquarters are in Södertälje, Sweden, and its manufacturing facilities employ 9,600 people in 16 different countries. The company operates fourteen research and development sites in eight countries and has sales in over 100 countries around the world. AstraZeneca focuses its pharmaceutical business on seven key therapeutic areas: anesthesia and pain control, cardiovascular, central nervous system, gastrointestinal (it is a world leader in this therapeutic area), infection, oncology, and respiratory. Its product range includes such blockbusters as Nexium, Crestor, Seroquel, and Symbicort. AstraZeneca was formed as the result of the 1999 merger of two European pharmaceuticals companies: Astra AB of Sweden, a maker of pharmaceutical products and medical devices, and Zeneca PLC of the United Kingdom, a bioscience company focusing on pharmaceuticals, agricultural and specialty chemicals, and disease-specific healthcare services. One year after its merger, the company achieved sales of US$15.8 billion, with an operating profit of US$4 billion. In 2011, company sales and operating profit were $33.6 billion and $13.2 billion respectively. AstraZeneca is one of the world's largest pharmaceutical companies, with FY2011 sales of $33.27 billion and...

Words: 1230 - Pages: 5

Finance

... scientific manpower, strength of national laboratories and an increasing balance of trade. The Pharmaceutical Industry, with its rich scientific talents and research capabilities, supported by Intellectual Property Protection regime is well set to take on the international market.  (b) Major competitors (Indian andGlobal): Indian Competitors 1. Aventis Pharma 2. GlaxoSmithKline 3. AstraZeneca 4. Zandu Realty 5. Dr Reddys Labs 6. Pfizer 7. Cipla 8. Sun Pharma 9. Ranbaxy Global Competitors 1. Johnson & Johnson 2. Amgen 3. Boston Scientific 4. Sanofi SA 5. Novo Nordisk A/S 6. GlaxoSmithKline PLC 7. AstraZeneca PLC (c) Market share of companies with data in terms of Rupee sales: (d) Market share: current and over time: Company | 2006 | 20007 | 2008 | 2009 | 2010 | Current | Astrazeneca Pharma India Ltd. | 246.42 | 293.68 | 330.51 | 374.34 | NA | 594.03 | Abbott India Ltd. | 530.78 | 620.29 | 691.43 | 790.21 | 972.86 | 1018.95 | Pfizer Ltd. | 724.15 | 791.98 | 794.27 | 786.73 | NA | 1244.64 | Aventis Pharma Ltd. | 868.47 | 951.81 | 961.13 | 1070.38 | 983.8 | 1159.6 | GlaxoSmithKline | 1593.86 | 1710.82 | 1761.39 | 1796.22 | 1773.4 | 2146.43 | Ranbaxy Laboratories Ltd. | 3284.03 | 3599.15 | 3656.2 | 3932.23 | 4198.9 | 5672.1 | Cipla Ltd. | 3103.81 | 3657.95 | 4295.24 | 5297.35 | 3763.7 | 6123.84 | Dr Reddy's Laboratories Ltd. | 2154.18 | 4196.69 | 3615.4 | 4531.5 | 4162.2 | 5249.07...

Words: 1006 - Pages: 5

Obu Sls

...Section 1 Learning from Meetings and Presentation My research report focusing on business and financial performance analysis of AstraZeneca over three year’s period. I had three meeting with my mentor, and I very appreciate her supports and advices for my research report. She showed me the direction from where I could start my project and reach to conclusion. And she pointed out problems that I had made and took enquiries from me. Therefore, there are many learning outcomes from meeting with my project mentor.  Preparation and implementation work. After discussed with my mentor, I realized that preparation is very important to make sure the objectives of the meetings can be achieved efficiently and successfully. A proper preparation can facilitate the discussion so that maximum benefits can be derived from the meetings. And I had prepared a timetable for the project timeline and also issues to be discussed in the meeting. According to the requirement of the first meeting with my project mentor, I have to know the research frame, goals, approach and the time arrangement. That means I should make the planning about the research. I choose AstraZeneca PLC as the topic of this study about the business and financial performance. As a pharmaceutical company, AstraZeneca achieves great development in the recent years which is worth studying its changes of financial performance and business. Furthermore, I adopt ratio analysis and model analysis for understanding clearly......

Words: 262 - Pages: 2

Gsk Patents

...Through analyzing the competitors of GSK, including Merck, AstraZeneca, Pfizer, Eli Lilly, Roche, Sanofi. We found that AstraZeneca and Pfizer are the biggest threats for GSK in many areas such as Respiratory, CNS disorders etc. Therefore, we compared GSK with these two companies to evaluate the competitive advantages of GSK. USD $ in millions, translated from GBP £     |   | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | Dec 31, 2009 | Dec 31, 2008 | | Land and buildings | 10,538  | 9,654  | 9,263  | 9,457  | 8,506  | | Plant, equipment and vehicles | 16,105  | 15,454  | 15,550  | 16,361  | 15,020  | | Assets in construction | 3,056  | 3,148  | 3,343  | 3,523  | 3,330  | | Property, plant and equipment, cost | 29,699  | 28,255  | 28,156  | 29,340  | 26,857  | | Accumulated depreciation | (15,427) | (14,663) | (14,234) | (14,184) | (12,708) | | Property, plant and equipment, net book value | 14,272  | 13,592  | 13,922  | 15,156  | 14,149  | Patents 2013年数据 Assignee | No. of patent families | No. of patent families as 1st assignee | GLAXOSMITHKLINE (UK) | 37 | 32 | SANOFI-AVENTIS  (FR) | 21 | 20 | US GOVERNMENT (US) | 21 | 12 | WYETH CORP (US) | 20 | 15 | NOVARTIS CORP (CH) | 19 | 13 | MERCK AND CO INC (US) | 15 | 14 | SEPPIC SA (FR) | 12 | 9 | BISEIBUTSU KAGAKU KENKYUSHO (JP) | 11 | 10 | KITASATO INST (JP) | 8 | 6 | PFIZER CORP (US) | 8 | 6 | AQUILA BIOPHARM INC (US) | 8 | 4 | UNIVERSITY OF CALIFORNIA (US) | 7 | 5 | EISAI...

Words: 383 - Pages: 2

Christina Health Care

...About Christiana Care Health System Christiana Care Health System, headquartered in Wilmington, Delaware, is one of the country's largest health care providers, ranking 22nd in the nation for hospital admissions. Christiana Care is a major teaching hospital with two campuses and more than 250 Medical-Dental residents and fellows. Christiana Care is recognized as a regional center for excellence in cardiology, cancer and women's health services. The system is home to Delaware’s only Level I trauma center, the only center of its kind between Philadelphia and Baltimore. Christiana Care also features a Level 3 neonatal intensive care unit, the only delivering hospital in the state to offer this level of care for newborns. A not-for-profit, non-sectarian health system, Christiana Care includes two hospitals with more than 1,100 patient beds, a home health care service, preventive medicine, rehabilitation services, a network of primary care physicians and an extensive range of outpatient services. With more than 10,500 employees, Christiana Care is the largest private employer in Delaware and the 10th largest employer in the Philadelphia region. In fiscal year 2013, Christiana Care had $2.51 billion in total patient revenue and provided the community with $27.3 million in charity care (at cost). WILMINGTON, Del. — The AstraZeneca HealthCare Foundation’s Connections for Cardiovascular HealthSM program today announced a grant of $213,094 to Christiana Care Health System to...

Words: 973 - Pages: 4

Intro to Corporate Strategy and Governance

...Corporate strategy, Governance and Ethics in the Global Environment A case study of AstraZeneca Introduction: The topic chosen for the assignment is ‘critical appraisal of the corporate strategy, governance and ethics of AstraZeneca within the global environment’. This assignment will be divided in four main parts. The first part will discuss the general background and reasons for choosing the topic. The second part will be the main body which is subdivided into following headings: * Critical consideration of the products, markets, divisions and subdivisions of AstraZeneca * Critical examination of AstraZeneca’s environment * Critical evaluation of how the organisation relates its competences to its environment via its strategy * Critical review of the impact of social, environmental, ethical, legal and governance issues on AstraZeneca * Critical assessment of how the organisation is currently enclosing these issues in its strategy and operations * Assess the extent to which the organisation is managing tensions between corporate responsibility and maximising shareholder value The third part will discuss the conclusions of the study. Finally, the bibliography and appendices will be included. Reasons for choosing the topic: I chose AstraZeneca to study the corporate strategy, governance and ethics for the assignment because it is one of the biggest biopharmaceutical companies in the whole world which develops, manufactures and sells......

Words: 261 - Pages: 2

Finance

...Financial decision making Contents Introduction: 1 Task: 1 1 (a) Ratio analysis on the basis of AstraZeneca Annual Report and Form 20-F Information 2012: 1 (b) Business structure and financial structure (comparison and relative advantages of the chosen organization) 5 (c) Compare and comment on the finances of business: 7 (d)Recommend potential investor for the investment decision: 8 (e)All possible Sources of finance for 500000 and best source 8 (f) Management of working capital: 10 Task 2: 11 (a)Preparations of a cash flow forecast and comment on budget and cash flow: 11 (b)Recommendation for managing cash flow: 12 Task 3: 12 (a)Assessment of projects by financial techniques: 12 (b) Recommendation from the above calculations and reason behind the choice: 13 Conclusions: 14 Reference: 15 Introduction: Finance is the paramount part of every organization. Whatever the size of the company, financing plays a vital role in the business organization. Ratio analysis is an important tool for the business decision as well as for the interpretation of the financial statements. We have selected AstraZeneca Annual Report & form 20-F information 2012. All the ratio analysis and decision in respect of the business structure as well as financial structure are based on this particular company. Investment appraisal techniques like- NPV, internal rate of return, payback period, accounting rate of return are based on the given data. This report suggests appropriate...

Words: 3459 - Pages: 14

Mncs in Mexico

...Marked socio-economic differences in Mexico are playing an important role in pushing the uptake of generics, and these issues are starting to affect multinational corporations (MNCs). MNCs are being forced to open up and diversify, quite simply to have their fingers in as many pies where they can compete successfully. Alternatively they are applying a more focused sales strategy to concentrate on niche markets. Alvarez Tostado of AstraZeneca believes that MNCs need to adjust their activities to become competitive in both the private and public sector. “Mexico provides a uniquely generous market structure where you have the institutional sector, the private out-of- pocket segment of the market, and then you have the new up-and-coming popular insurance systems that will cater to those who have very little access to medical care, if they have access at all. So in that regard, I think the industry has to realign itself to make sure that it is able to provide adequate services to the institutional sector; provide broadened access to the out-of-pocket consumer, and obviously realign to be competitive in the Seguro Popular concept.” Mexico is no exception to the global trend of companies moving towards branded generics, a successfully growing sector in a very much brand-driven Mexican society. Bertrand Baron, general director of Sanofi Mexico, is confident that Sanofi’s global strategy of diversification fits well with the current climate in Mexico. “I believe that Sanofi in...

Words: 453 - Pages: 2

Aci Company Profile

... ,ophthalmic and injection forms. ACI also markets world-renowned branded pharmaceutical products like Arimidex, Casodex, Zoladex, Atarax etc. from world-class multinational companies like ASTRAZENECA, UK and UCB, BELGIUM in Bangladesh.ACI is actively engaged in introducing newer molecules and Novel Drug Delivery Systems (NDDS) to meet the needs of the future.ACI introduced the concept of quality management system by being the first company in Bangladesh to achieve ISO 9001 certification in 1995 and follows the policy of continuous improvement in all its operations.Aligned with the concept that a pharmaceutical must ensure effective management of environment, ACI complies with standard environment management policy, thus adorned with EMS 14001 in 2000. ACI maintains a congenial and supportive relationship with the healthcare community of Bangladesh, with the belief that business excellence can only be achieved through pursuit of quality by understanding, accepting, meeting and exceeding customer expectations.The management of ACI, a competent team of professionals, thus operates with a progressive attitude to provide effective solutions to satisfy the customers’ needs, through its products and services of uncompromising quality.ACI values are embodied in its mission and vision statements. ACI quality and environmental concerns are clearly stated through declared policies. What was primarily a Pharmaceutical business in 1992 with a turnover of Tk.80 million with stagnant......

Words: 676 - Pages: 3

Business Ethic

...Pfizer is a pharmaceutical company that is global based. They produce medicines for people around the world and it claims that “good health is vital” t o them. They also claim to use justifiable means in producing medicines that are needed in the world using science and their global resources. They produce medicines that prevent diseases and they are working towards coming up with new products that will prevent/cure challenging diseases that we see in our daily lives like Alzheimer’s and cancer. They are focused on their customers and their shareholders has they strive to be transparent and listening to the people who are involved in making decisions about health issues. Recently, Pfizer has had some problems (they failed to take over the British company AstraZeneca, much to the chagrin of many) and scandals that are usually associated with pharmaceutical companies like animal testing, testing drugs on children to mention but a few. In 2012, it also paid about $60 million to settle charges of bribery. A lot of multinational/global companies make very good case studies on ethics and Pfizer is one of those. Using your research of the company complete the following questions; 2.1: Explain how Pfizer’s objectives are affected by ethical considerations . (M1). You are required to explain Pfizer’s corporate objectives and how they are affected by ethical considerations. Consider; response to ethical pressures, implementing ethical practices, public image, UK......

Words: 321 - Pages: 2

Finanacial

... points to the rising wealth of people in emerging markets: 'As affluence increases so will their ability to afford improved medical care. China, Brazil and India have huge populations. 'Over the long term that means increased spending on healthcare and drugs and pharmaceuticals and medical devices. Potentially that offers great rewards for the companies offering these services. TANYA JEFFERIES, 2014. Should you put your money into the firms hoping to beat cancer? Biotech and healthcare funds race ahead this year - but investors should tread carefully. [Online]. Available at: http://www.thisismoney.co.uk/money/investing/article-2857653/Should-invest-biotech-money-firms-hoping-beat-cancer.html#ixzz3rfv8fDjo [accessed 16/11/15]. "Some people haven't liked AstraZeneca for years," Woodford said last year. "People were calling the management lunatics for the level of spending committed to research and development, but I didn't think they were lunatics, and now it is paying off. "The key to the valuation of AstraZeneca is its pipeline of new drugs. It is immersed in technology, but people don't regard it as a technology stock because it doesn't have a bloke in jeans and a T-shirt representing it."The pipeline Woodford points to very much reflects some of the themes fund managers such as Borho and Pinniger are so excited about. AstraZeneca has a world-leading immune-oncology portfolio, with 13 drugs already in clinical trials and another 16 at the planning stage. With a...

Words: 799 - Pages: 4

Pfizer Drops Astrazeneca Takeover After Dispute

...Feature Article John Doe English 12 Acc - Journalism Pfizer Drops AstraZeneca Takeover After Dispute (May 25, 2014) “Our final proposal was compelling and represented full value for AstraZeneca” is the statement given by Pfizer chief executive Ian Read speaking on Pfizer’s bid for fellow pharmaceutical giant AstraZeneca. Following a month long, public dispute between the two pharmaceutical giants, Pfizer is backing out of the $118 billion merger of the two companies. The conflict centers primarily on share price disputes between the two companies. The news of the failed deal gives AstraZenca investors mixed reactions. Investors may now force more pressure upon the board of the Anglo-Swedish AstraZeneca in order to produce higher returns. Some shareholders such as Aberdeen Asset Manangement believe that Pfizer’s bid is too low. Others such as Jupiter Fund Management believe that AstraZeneca is missing a beneficial opportunity. The details of the deal are complicated, but the main components of the dispute revolve around increasing Pfizer’s share prices. After four previous attempts to make a deal, Pfizer is unable to raise the $75.05 per share that AstraZeneca is asking to obtain. In short, AstraZeneca believes that Pfizer is not offering fair monetary and stock compensation for the company, and therefore has allowed the deadline for the deal’s completion to pass. Following the news of the deal’s failure, AstraZeneca shares have fallen by...

Words: 487 - Pages: 2

Report on Capital Structure and the Cost of Capital of Astrazeneca Plc and British American Tobacco Plc.

...Report on Capital Structure and the Cost of Capital of AstraZeneca Plc and British American Tobacco Plc. Table of Contents 1.0 Introduction………………………………………… 4 2.0 Background………………………………………… 5 3.0 Capital Structure…………………………………… 6 3.1 Debt to equity……………………………… 6 3.2 Long term debt to equity…………………... 7 3.3 Total debt to capital………………………… 7 3.4 Long term debt to capital…………………... 8 3.5 Balance sheet structure AZN………………. 9 3.6 Balance sheet structure BAT………………. 10 3.7 Discussion…………………………………. 10-11 4.0 Cost of capital……………………………………… 12 4.1 Introduction………………………………... 12 4.2 Weighted average cost of capital………….. 12 4.3 Dividend growth model…………………… 12-14 4.4 Capital asset pricing model………………... 14-16 4.5 Discussion…………………………………. 16-17 5.0 References…………………………………………. 18 6.0 Link to excel workbook……………………………. 18 Capital Structure and the Cost of Capital 1.0 Introduction This report provides financial analysis of two top publicly traded companies from very different sectors. AstraZeneca Plc(AZN) and British American Tobacco Plc(BAT). The structure of the report will be aimed at meeting the objectives of the brief: Empirical observation Comparative analysis Impact of industry conditions Economic environment Business environment For consistency of information all the data used, unless otherwise stated, is obtained from ThomsonONE...

Words: 2834 - Pages: 12